<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02608242</url>
  </required_header>
  <id_info>
    <org_study_id>YH22189-102</org_study_id>
    <nct_id>NCT02608242</nct_id>
  </id_info>
  <brief_title>PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22189 in Comparison to Telmisartan/Amlodipine and Rosuvastatin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Randomized, open-label, single-dose, 3-treatment, 3-period, 3-sequence crossover
      design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 6 by 3 cross-over study to evaluate pharmacokinetics of YH22189 FDC compared to
      reference telmisartan/amlodipine and rosuvastatin co-administered in three groups enrolling
      healthy adult male subjects under fasting conditions.

      Subjects will be admitted to the clinic in the evening before Day 1. All subjects will
      receive a single oral dose of YH22189 FDC or telmisartan/amlodipine or rosuvastatin
      administered in the morning on Day 1. All the subjects will remain in the clinical unit until
      completion of all assessments on Day 2 including collection post-dose PK sample. Subjects
      will return to the clinic for pharmacokinetic samples at scheduled time. The three treatment
      periods will be separated by a washout period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    sponsor decision
  </why_stopped>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Telmisartan Cmax</measure>
    <time_frame>0 - 72 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Telmisartan AUClast</measure>
    <time_frame>0 - 72 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amlodipine Cmax</measure>
    <time_frame>0 - 168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amlodipine AUClast</measure>
    <time_frame>0 - 168 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rosuvastatin Cmax</measure>
    <time_frame>0 - 48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rosuvastatin AUClast</measure>
    <time_frame>0 - 48 hrs</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>YH22189</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YH22189 FDC tablet of Yuhan Corporation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twynsta 80/10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan/Amlodipine 80/10mg (FDC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crestor 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH22189</intervention_name>
    <arm_group_label>YH22189</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Twynsta 80/10mg</intervention_name>
    <arm_group_label>Twynsta 80/10mg</arm_group_label>
    <other_name>Telmisartan/Amlodipine 80/10mg(FDC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crestor 20mg</intervention_name>
    <arm_group_label>Crestor 20mg</arm_group_label>
    <other_name>Rosuvastatin 20mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female with a body mass index(BMI) between 18.5 and 25 kg/m2

          -  Who has not suffered from clinically significant disease

          -  Provision of signed written informed consent

        Exclusion Criteria:

          -  History of and clinically significant disease

          -  A history of drug abuse or the presence of positive reactions to drugs that have abuse
             potential in urine screenings for drugs

          -  Administration of other investigational products within 3 months prior to the first
             dosing

          -  Volunteers considered not eligible for the clinical trial by the investigator (study
             doctor) due to reasons including laboratory test results, ECGs, or vital signs

          -  Sitting blood pressure meeting the following criteria at screening: 150 ≥ systolic
             blood pressure ≤100 (mmHg) and 100 ≥ diastolic blood pressure ≤ 60 (mmHg)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Chunju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

